A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

PHASE3CompletedINTERVENTIONAL
Enrollment

642

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Chronic Kidney DiseaseDialysisHyperphosphatemiaDyslipidemia
Interventions
DRUG

MCI-196

3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study

DRUG

Placebo

3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study

Trial Locations (73)

Unknown

Ajka

Baja

Budapest

Esztergom

Győr

Hatvan

Kisvárda

Lecco

Modena

Pavia

Roma

Alor Star

Ipoh

Kajang

Klang

Kota Kinabalu

Kuala Terengganu

Kuantan

Kuching

Malacca

Seremban

Taiping

Skopje

Lodz

Poznan

Płock

Rybnik

Warsaw

Wroclaw

Zielona Góra

Arkhangelsk

Armavir

Chelyabinsk

Chita

Irkutsk

Ivanovo

Kaluga

Kemerovo

Khabarovsk

Krasnodar

Krasnoyarsk

Moscow

Nizhny Novgorod

Novokuznetsk

Novorossiysk

Novosibirsk

Omsk

Petrozavodsk

Rostov-on-Don

Saint Petersburg

Smolensk

Tomsk

Tver'

Tyumen

Vladimir

Vladivostok

Volzhskiy

Yaroslavl

Yekaterinburg

Belgrade

Kragujevac

Niš

Novi Sad

Chernivtsi

Dnipro

Ivano-Frankivsk

Kharkiv

Kiev

Mykolaiv

Ternopil

Uzhhorod

Zaporizhya

Zhytomyr

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY